A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

被引：75

作者：

Bando, Hideaki ^{[1
]}

Kagawa, Yoshinori ^{[2
]}

Kato, Takeshi ^{[3
]}

Akagi, Kiwamu ^{[4
]}

Denda, Tadamichi ^{[5
]}

Nishina, Tomohiro ^{[6
]}

Komatsu, Yoshito ^{[7
]}

Oki, Eiji ^{[8
]}

Kudo, Toshihiro ^{[9
]}

Kumamoto, Hiroshi ^{[10
]}

Yamanaka, Takeharu ^{[11
]}

Yoshino, Takayuki ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[2] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan

[3] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Osaka, Japan

[4] Saitama Canc Ctr, Div Mol Diag & Canc Prevent, Ina, Saitama, Japan

[5] Chiba Canc Ctr, Div Gastroenterol, Chiba, Chiba, Japan

[6] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan

[7] Hokkaido Univ, Dept Canc Chemotherapy, Hosp Canc Ctr, Sapporo, Hokkaido, Japan

[8] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka, Japan

[9] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan

[10] Sysmex Corp, Sci Affairs Div, Clin Affairs, Kobe, Hyogo, Japan

[11] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Kanagawa, Japan

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 10期

关键词：

PLUS CETUXIMAB TREATMENT; MANAGEMENT;

D O I：

10.1038/s41416-019-0457-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

BACKGROUND: OncoBEAM (TM) RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal cancer (mCRC). We conducted a multicentre, prospective study to investigate the concordance of the RAS mutational status between plasma ctDNA and tumour tissue DNA. METHODS: mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- and tissue-based RAS mutational status were determined by BEAMing, respectively. RESULTS: A total of 280 patients from eight institutions were eligible. The overall agreement between plasma- and tissue-based analyses was 86.4%, with a positive percent agreement of 82.1% and negative percent agreement of 90.4%. From logistic regression analysis, lung metastasis alone indicated the most significant factor associated with discordance. The agreement between plasma- and tissue-based analyses was 64.5% in patients with lung metastasis alone (n = 31) indicating lower amount of ctDNA. Among the cases with lung metastasis alone, all plasma- and tissue-based analyses were perfectly concordant in cases with >= 20 mm of maximum lesion diameter or >= 10 lesions. CONCLUSION: The clinical validity of OncoBEAM (TM) RAS CRC kit was confirmed. Careful attention should be paid for mCRC patients with lung metastases alone having fewer metastases or smaller diameter lesions.

引用

页码：982 / 986

页数：5

共 15 条

[1]

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].

Bettegowda, Chetan ;

Sausen, Mark ;

Leary, Rebecca J. ;

Kinde, Isaac ;

Wang, Yuxuan ;

Agrawal, Nishant ;

Bartlett, Bjarne R. ;

Wang, Hao ;

Luber, Brandon ;

Alani, Rhoda M. ;

Antonarakis, Emmanuel S. ;

Azad, Nilofer S. ;

Bardelli, Alberto ;

Brem, Henry ;

Cameron, John L. ;

Lee, Clarence C. ;

Fecher, Leslie A. ;

Gallia, Gary L. ;

Gibbs, Peter ;

Le, Dung ;

Giuntoli, Robert L. ;

Goggins, Michael ;

Hogarty, Michael D. ;

Holdhoff, Matthias ;

Hong, Seung-Mo ;

Jiao, Yuchen ;

Juhl, Hartmut H. ;

Kim, Jenny J. ;

Siravegna, Giulia ;

Laheru, Daniel A. ;

Lauricella, Calogero ;

Lim, Michael ;

Lipson, Evan J. ;

Marie, Suely Kazue Nagahashi ;

Netto, George J. ;

Oliner, Kelly S. ;

Olivi, Alessandro ;

Olsson, Louise ;

Riggins, Gregory J. ;

Sartore-Bianchi, Andrea ;

Schmidt, Kerstin ;

Shih, Ie-Ming ;

Oba-Shinjo, Sueli Mieko ;

Siena, Salvatore ;

Theodorescu, Dan ;

Tie, Jeanne ;

Harkins, Timothy T. ;

Veronese, Silvio ;

Wang, Tian-Li ;

Weingart, Jon D. .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[2]

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer [J].

Bokemeyer, C. ;

Koehne, C. -H. ;

Ciardiello, F. ;

Lenz, H. -J. ;

Heinemann, V. ;

Klinkhardt, U. ;

Beier, F. ;

Duecker, K. ;

van Krieken, J. H. ;

Tejpar, S. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1243-1252

[3]

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review [J].

Garcia-Foncillas, J. ;

Alba, E. ;

Aranda, E. ;

Diaz-Rubio, E. ;

Lopez-Lopez, R. ;

Tabernero, J. ;

Vivancos, A. .

ANNALS OF ONCOLOGY, 2017, 28 (12) :2943-2949

[4]

Garcia- Foncillas J., BR J CANC, V119, P1464

[5]

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer [J].

Grasselli, J. ;

Elez, E. ;

Caratu, G. ;

Matito, J. ;

Santos, C. ;

Macarulla, T. ;

Vidal, J. ;

Garcia, M. ;

Vieitez, J. M. ;

Paez, D. ;

Falco, E. ;

Lopez Lopez, C. ;

Aranda, E. ;

Jones, F. ;

Sikri, V. ;

Nuciforo, P. ;

Fasani, R. ;

Tabernero, J. ;

Montagut, C. ;

Azuara, D. ;

Dienstmann, R. ;

Salazar, R. ;

Vivancos, A. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1294-1301

[6]

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer [J].

Misale, Sandra ;

Yaeger, Rona ;

Hobor, Sebastijan ;

Scala, Elisa ;

Janakiraman, Manickam ;

Liska, David ;

Valtorta, Emanuele ;

Schiavo, Roberta ;

Buscarino, Michela ;

Siravegna, Giulia ;

Bencardino, Katia ;

Cercek, Andrea ;

Chen, Chin-Tung ;

Veronese, Silvio ;

Zanon, Carlo ;

Sartore-Bianchi, Andrea ;

Gambacorta, Marcello ;

Gallicchio, Margherita ;

Vakiani, Efsevia ;

Boscaro, Valentina ;

Medico, Enzo ;

Weiser, Martin ;

Siena, Salvatore ;

Di Nicolantonio, Federica ;

Solit, David ;

Bardelli, Alberto .

NATURE, 2012, 486 (7404) :532-U131

[7]

Serial assessment of human tumor burdens in mice by the analysis of circulating DNA [J].

Rago, Carlo ;

Huso, David L. ;

Diehl, Frank ;

Karim, Baktiar ;

Liu, Guosheng ;

Papadopoulos, Nickolas ;

Samuels, Yardena ;

Velculescu, Victor E. ;

Vogelstein, Bert ;

Kinzler, Kenneth W. ;

Diaz, Luis A., Jr. .

CANCER RESEARCH, 2007, 67 (19) :9364-9370

[8]

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing [J].

Schmiegel, Wolff ;

Scott, Rodney J. ;

Dooley, Susan ;

Lewis, Wendy ;

Meldrum, Cliff J. ;

Pockney, Peter ;

Draganic, Brian ;

Smith, Steve ;

Hewitt, Chelsee ;

Philimore, Hazel ;

Lucas, Amanda ;

Shi, Elva ;

Namdarian, Kateh ;

Chan, Timmy ;

Acosta, Danilo ;

Ping-Chang, Su ;

Tannapfel, Andrea ;

Reinacher-Schick, Anke ;

Uhl, Waldemar ;

Teschendorf, Christian ;

Wolters, Heiner ;

Stern, Josef ;

Viebahn, Richard ;

Friess, Helmut ;

Janssen, Klaus-Peter ;

Nitsche, Ulrich ;

Slotta-Huspenina, Julia ;

Pohl, Michael ;

Vangala, Deepak ;

Baraniskin, Alexander ;

Dockhorn-Dworniczak, Barbara ;

Hegewisch-Becker, Susanne ;

Ronga, Philippe ;

Edelstein, Daniel L. ;

Jones, Frederick S. ;

Hahn, Stephan ;

Fox, Stephen B. .

MOLECULAR ONCOLOGY, 2017, 11 (02) :208-219

[9]

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients [J].

Shitara, K. ;

Yamanaka, T. ;

Denda, T. ;

Tsuji, Y. ;

Shinozaki, K. ;

Komatsu, Y. ;

Kobayashi, Y. ;

Furuse, J. ;

Okuda, H. ;

Asayama, M. ;

Akiyoshi, K. ;

Kagawa, Y. ;

Kato, T. ;

Oki, E. ;

Ando, T. ;

Hagiwara, Y. ;

Ohashi, Y. ;

Yoshino, T. .

ANNALS OF ONCOLOGY, 2019, 30 (02) :259-265

[10]

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer [J].

Van Cutsem, Eric ;

Lenz, Heinz-Josef ;

Koehne, Claus-Henning ;

Heinemann, Volker ;

Tejpar, Sabine ;

Melezinek, Ivan ;

Beier, Frank ;

Stroh, Christopher ;

Rougier, Philippe ;

van Krieken, J. Han ;

Ciardiello, Fortunato .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) :692-700

← 1 2 →